In a groundbreaking theory, scientists at Arizona State University's Biodesign Institute propose a unifying explanation for the molecular chaos driving Alzheimer's disease.

Charles Piller, author of the new book Doctored, says the scientific community needs “to take a good hard look in the mirror.

Annovis Bio has commenced the treatment of first two subjects in a randomised Phase III clinical trial to assess the efficacy and safety of buntanetap in treating early Alzheimer's disease (AD). The ...

In a novel theory, scientists at Arizona State University's Biodesign Institute propose a unifying explanation for the ...

HOUSTON - Coya Therapeutics, Inc. (NASDAQ: COYA), a $109.1 million market cap biotechnology company focusing on regulatory T ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the ...

There's currently no cure for dementia. Although some recently developed drugs show promise in slowing the progress of the ...

Able to cross the blood-brain barrier, Xenon gas seemed to perk the mice right up, which began to become particularly active ...

A research team has discovered that the two key pathological hallmarks of Alzheimer's -- tau protein and beta-amyloid -- affect brain circuits in distinct yet synergistic ways, particularly those ...

A new platform for studying neuroinflammatory diseases, utilizing advanced 3D bioprinting technology has been developed.

Alzheimer’s is a mind-body malaise that experts say can take up to 20 years to run its fearsome course—like having a sliver ...

SaveHealth provides an overview of Alzheimer's disease, including treatment and coping mechanisms for those with the disease ...